A Closer Look: Taiwan’s TLC And Ablynx Target Next-gen Liposome-Antibody Combos
This article was originally published in PharmAsia News
Executive Summary
Belgium biotech Ablynx adds Taiwan Liposome to its long line of partnerships, and the two embark on a journey to discover whether combining Ablynx’s nanobody targeting agents and TLC’s liposome delivery platform will improve oncology drug efficacy and reduce toxicity.